respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.carisoprodol increases toxicity of oliceridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. Monitor for signs of urinary retention or reduced gastric motility if oliceridine is coadministered with anticholinergics.ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC)ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC) decreases effects of carisoprodol by unspecified interaction mechanism. Modify Therapy/Monitor Closely. Increase dose if clinically indicated.opium tincturecarisoprodol and opium tincture both increase sedation. Use Caution/Monitor.orphenadrinecarisoprodol and orphenadrine both increase sedation. Use Caution/Monitor.oxazepamoxazepam and carisoprodol both increase sedation. Use Caution/Monitor.oxycodonecarisoprodol and oxycodone both increase sedation. Use Caution/Monitor.oxymorphonecarisoprodol and oxymorphone both increase sedation. Use Caution/Monitor.paliperidonecarisoprodol and paliperidone both increase sedation. Use Caution/Monitor.papaveretumcarisoprodol and papaveretum both increase sedation. Use Caution/Monitor.papaverinecarisoprodol and papaverine both increase sedation. Use Caution/Monitor.pentazocinecarisoprodol and pentazocine both increase sedation. Use Caution/Monitor.pentobarbitalpentobarbital and carisoprodol both increase sedation. Use Caution/Monitor.perphenazinecarisoprodol and perphenazine both increase sedation. Use Caution/Monitor.phenobarbitalphenobarbital and carisoprodol both increase sedation. Use Caution/Monitor.phenylephrine POcarisoprodol increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. .pholcodinecarisoprodol and pholcodine both increase sedation. Use Caution/Monitor.pimozidecarisoprodol and pimozide both increase sedation. Use Caution/Monitor.prabotulinumtoxinAcarisoprodol increases effects of prabotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade.primidoneprimidone and carisoprodol both increase sedation. Use Caution/Monitor.prochlorperazinecarisoprodol and prochlorperazine both increase sedation. Use Caution/Monitor.promethazinepromethazine and carisoprodol both increase sedation. Use Caution/Monitor.propofolpropofol and carisoprodol both increase sedation. Use Caution/Monitor.propylhexedrinecarisoprodol increases and propylhexedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.protriptylinecarisoprodol and protriptyline both increase sedation. Use Caution/Monitor.quazepamquazepam and carisoprodol both increase sedation. Use Caution/Monitor.quetiapinecarisoprodol and quetiapine both increase sedation. Use Caution/Monitor.ramelteoncarisoprodol and ramelteon both increase sedation. Use Caution/Monitor.remimazolamremimazolam, carisoprodol. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely. Coadministration may result in profound sedation, respiratory depression, coma, and/or death. Continuously monitor vital signs during sedation and recovery period if coadministered. Carefully titrate remimazolam dose if administered with opioid analgesics and/or sedative/hypnotics.risperidonecarisoprodol and risperidone both increase sedation. Use Caution/Monitor.rucaparibrucaparib will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Adjust dosage of CYP2C19 substrates, if clinically indicated.scullcapcarisoprodol and scullcap both increase sedation. Use Caution/Monitor.secobarbitalsecobarbital and carisoprodol both increase sedation. Use Caution/Monitor.shepherd's pursecarisoprodol and shepherd's purse both increase sedation. Use Caution/Monitor.sparsentansparsentan will decrease the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. stiripentolstiripentol will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the dose of CYP2C19 substrates, if adverse reactions are experienced when administered concomitantly with stiripentol.stiripentol, carisoprodol. Either increases effects of the other by sedation. Use Caution/Monitor. Concurrent use of medications with CNS depressant effects together with thalidomide should be avoided due to the risk for additive sedative effects.sufentanilcarisoprodol and sufentanil both increase sedation. Use Caution/Monitor.tapentadolcarisoprodol and tapentadol both increase sedation. Use Caution/Monitor.tecovirimattecovirimat will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Tecovirimat is a weak inhibitor of CYP2C8 and CYP2C19. Monitor for adverse effects if coadministered with sensitive substrates of these enzymes.temazepamtemazepam and carisoprodol both increase sedation. Use Caution/Monitor.thioridazinecarisoprodol and thioridazine both increase sedation. Use Caution/Monitor.thiothixenecarisoprodol and thiothixene both increase sedation. Use Caution/Monitor.topiramatecarisoprodol and topiramate both increase sedation. Modify Therapy/Monitor Closely.tramadolcarisoprodol and tramadol both increase sedation. Use Caution/Monitor.trazodonecarisoprodol and trazodone both increase sedation. Use Caution/Monitor.triazolamtriazolam and carisoprodol both increase sedation. Use Caution/Monitor.triclabendazoletriclabendazole will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. If plasma concentrations of the CYP2C19 substrates are elevated during triclabendazole, recheck plasma concentration of the CYP2C19 substrates after discontinuation of triclabendazole. triclofostriclofos and carisoprodol both increase sedation. Use Caution/Monitor.trifluoperazinecarisoprodol and trifluoperazine both increase sedation. Use Caution/Monitor.trimipraminecarisoprodol and trimipramine both increase sedation. Use Caution/Monitor.xylometazolinecarisoprodol increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.ziconotidecarisoprodol and ziconotide both increase sedation. Use Caution/Monitor.ziprasidonecarisoprodol and ziprasidone both increase sedation. Use Caution/Monitor.zotepinecarisoprodol and zotepine both increase sedation. Use Caution/Monitor.Minor (2)eucalyptuscarisoprodol and eucalyptus both increase sedation. Minor/Significance Unknown.sagecarisoprodol and sage both increase sedation. Minor/Significance Unknown.abobotulinumtoxinAMonitor Closely (1)carisoprodol increases effects of abobotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade.acrivastineMonitor Closely (1)acrivastine and carisoprodol both increase sedation. Use Caution/Monitor.alfentanilMonitor Closely (1)carisoprodol and alfentanil both increase sedation. Use Caution/Monitor.alprazolamMonitor Closely (1)alprazolam and carisoprodol both increase sedation. Use Caution/Monitor.amisulprideMonitor Closely (1)amisulpride and carisoprodol both increase sedation. Use Caution/Monitor.amitriptylineMonitor Closely (1)carisoprodol and amitriptyline both increase sedation. Use Caution/Monitor.amobarbitalMonitor Closely (1)amobarbital and carisoprodol both increase sedation. Use Caution/Monitor.amoxapineMonitor Closely (1)carisoprodol and amoxapine both increase sedation. Use Caution/Monitor.apalutamideSerious - Use Alternative (1)apalutamide will decrease the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug. Coadministration of apalutamide, a strong CYP2C19 inducer, with drugs that are CYP2C19 substrates can result in lower exposure to these medications. Avoid or substitute another drug for these medications when possible. Evaluate for loss of therapeutic effect if medication must be coadministered.apomorphineMonitor Closely (1)carisoprodol and apomorphine both increase sedation. Use Caution/Monitor.aripiprazoleMonitor Closely (1)carisoprodol and aripiprazole both increase sedation. Use Caution/Monitor.asenapineMonitor Closely (1)asenapine and carisoprodol both increase sedation. Use Caution/Monitor.asenapine transdermalMonitor Closely (1)asenapine transdermal and carisoprodol both increase sedation. Use Caution/Monitor.avapritinibMonitor Closely (1)avapritinib and carisoprodol both increase sedation. Use Caution/Monitor.azelastineMonitor Closely (1)azelastine and carisoprodol both increase sedation. Use Caution/Monitor.baclofenMonitor Closely (1)baclofen and carisoprodol both increase sedation. Use Caution/Monitor.belladonna and opiumMonitor Closely (1)carisoprodol and belladonna and opium both increase sedation. Use Caution/Monitor.benperidolMonitor Closely (1)carisoprodol and benperidol both increase sedation. Use Caution/Monitor.benzhydrocodone/acetaminophenSerious - Use Alternative (2)benzhydrocodone/acetaminophen, carisoprodol. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation. benzhydrocodone/acetaminophen and carisoprodol both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequatebenzphetamineMonitor Closely (1)carisoprodol increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.brexanoloneMonitor Closely (1)brexanolone, carisoprodol. Either increases toxicity of the other by sedation. Use Caution/Monitor.brexpiprazoleMonitor Closely (1)brexpiprazole and carisoprodol both increase sedation. Use Caution/Monitor.brimonidineMonitor Closely (1)brimonidine and carisoprodol both increase sedation. Use Caution/Monitor.brivaracetamMonitor Closely (1)brivaracetam and carisoprodol both increase sedation. Use Caution/Monitor.brompheniramineMonitor Closely (1)brompheniramine and carisoprodol both increase sedation. Use Caution/Monitor.buprenorphineMonitor Closely (1)carisoprodol and buprenorphine both increase sedation. Use Caution/Monitor.buprenorphine buccalMonitor Closely (1)carisoprodol and buprenorphine buccal both increase sedation. Use Caution/Monitor.buprenorphine subdermal implantSerious - Use Alternative (1)buprenorphine subdermal implant and carisoprodol both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequatebuprenorphine transdermalSerious - Use Alternative (1)buprenorphine transdermal and carisoprodol both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequatebuprenorphine, long-acting injectionMonitor Closely (1)buprenorphine, long-acting injection increases effects of carisoprodol by Other (see comment). Modify Therapy/Monitor Closely. Comment: Buprenorphine may enhance the neuromuscular blocking action of skeletal muscle relaxants and increase risk for respiratory depression. Monitor for signs of respiratory depression that may be greater than otherwise expected and decrease muscle relaxant dosage as necessary.Serious - Use Alternative (1)buprenorphine, long-acting injection and carisoprodol both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequatebutabarbitalMonitor Closely (1)butabarbital and carisoprodol both increase sedation. Use Caution/Monitor.butalbitalMonitor Closely (1)butalbital and carisoprodol both increase sedation. Use Caution/Monitor.butorphanolMonitor Closely (1)carisoprodol and butorphanol both increase sedation. Use Caution/Monitor.calcium/magnesium/potassium/sodium oxybatesSerious - Use Alternative (1)carisoprodol, calcium/magnesium/potassium/sodium oxybates. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.cannabidiolMonitor Closely (1)cannabidiol will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the dose of sensitive CYP2C19 substrates, as clinically appropriate, when coadministered with cannabidiol. carbinoxamineMonitor Closely (1)carbinoxamine and carisoprodol both increase sedation. Use Caution/Monitor.cenobamateMonitor Closely (2)cenobamate, carisoprodol. Either increases effects of the other by sedation. Use Caution/Monitor. cenobamate will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider a dose reduction of CYP2C19 substrates, as clinically appropriate, when used concomitantly with cenobamate. chloral hydrateMonitor Closely (1)chloral hydrate and carisoprodol both increase sedation. Use Caution/Monitor.chlordiazepoxideMonitor Closely (1)chlordiazepoxide and carisoprodol both increase sedation. Use Caution/Monitor.chlorpheniramineMonitor Closely (1)chlorpheniramine and carisoprodol both increase sedation. Use Caution/Monitor.chlorpromazineMonitor Closely (1)carisoprodol and chlorpromazine both increase sedation. Use Caution/Monitor.cinnarizineMonitor Closely (1)cinnarizine and carisoprodol both increase sedation. Use Caution/Monitor.clemastineMonitor Closely (1)clemastine and carisoprodol both increase sedation. Use Caution/Monitor.clobazamMonitor Closely (1)carisoprodol, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).clomipramineMonitor Closely (1)carisoprodol and clomipramine both increase sedation. Use Caution/Monitor.clonazepamMonitor Closely (1)clonazepam and carisoprodol both increase sedation. Use Caution/Monitor.clorazepateMonitor Closely (1)clorazepate and carisoprodol both increase sedation. Use Caution/Monitor.clozapineMonitor Closely (1)carisoprodol and clozapine both increase sedation. Use Caution/Monitor.codeineMonitor Closely (1)carisoprodol and codeine both increase sedation. Use Caution/Monitor.cyclizineMonitor Closely (1)cyclizine and carisoprodol both increase sedation. Use Caution/Monitor.cyclobenzaprineMonitor Closely (1)carisoprodol and cyclobenzaprine both increase sedation. Use Caution/Monitor.cyproheptadineMonitor Closely (1)cyproheptadine and carisoprodol both increase sedation. Use Caution/Monitor.dantroleneMonitor Closely (1)carisoprodol and dantrolene both increase sedation. Use Caution/Monitor.daridorexantMonitor Closely (1)carisoprodol and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. desipramineMonitor Closely (1)carisoprodol and desipramine both increase sedation. Use Caution/Monitor.dexchlorpheniramineMonitor Closely (1)dexchlorpheniramine and carisoprodol both increase sedation. Use Caution/Monitor.dexfenfluramineMonitor Closely (1)carisoprodol increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dexmedetomidineMonitor Closely (1)dexmedetomidine and carisoprodol both increase sedation. Use Caution/Monitor.dextromoramideMonitor Closely (1)carisoprodol and dextromoramide both increase sedation. Use Caution/Monitor.diamorphineMonitor Closely (1)carisoprodol and diamorphine both increase sedation. Use Caution/Monitor.diazepamMonitor Closely (1)diazepam and carisoprodol both increase sedation. Use Caution/Monitor.diazepam intranasalMonitor Closely (1)diazepam intranasal, carisoprodol. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.difelikefalinMonitor Closely (1)difelikefalin and carisoprodol both increase sedation. Use Caution/Monitor.difenoxin hclMonitor Closely (1)carisoprodol and difenoxin hcl both increase sedation. Use Caution/Monitor.dimenhydrinateMonitor Closely (1)dimenhydrinate and carisoprodol both increase sedation. Use Caution/Monitor.diphenhydramineMonitor Closely (1)diphenhydramine and carisoprodol both increase sedation. Use Caution/Monitor.diphenoxylate hclMonitor Closely (1)carisoprodol and diphenoxylate hcl both increase sedation. Use Caution/Monitor.dipipanoneMonitor Closely (1)carisoprodol and dipipanone both increase sedation. Use Caution/Monitor.dopexamineMonitor Closely (1)carisoprodol increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dosulepinMonitor Closely (1)carisoprodol and dosulepin both increase sedation. Use Caution/Monitor.doxepinMonitor Closely (1)carisoprodol and doxepin both increase sedation. Use Caution/Monitor.doxylamineMonitor Closely (1)doxylamine and carisoprodol both increase sedation. Use Caution/Monitor.droperidolMonitor Closely (1)carisoprodol and droperidol both increase sedation. Use Caution/Monitor.elagolixMonitor Closely (1)elagolix will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak CYP2C19 inhibitor. Caution with sensitive CYP2C19 substrates.esketamine intranasalMonitor Closely (1)esketamine intranasal, carisoprodol. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.eslicarbazepine acetateMonitor Closely (1)eslicarbazepine acetate will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.estazolamMonitor Closely (1)estazolam and carisoprodol both increase sedation. Use Caution/Monitor.ethanolMonitor Closely (1)carisoprodol and ethanol both increase sedation. Use Caution/Monitor.etomidateMonitor Closely (1)etomidate and carisoprodol both increase sedation. Use Caution/Monitor.eucalyptusMinor (1)carisoprodol and eucalyptus both increase sedation. Minor/Significance Unknown.fedratinibMonitor Closely (1)fedratinib will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP2C19 substrates as necessary.fenfluramineMonitor Closely (1)carisoprodol increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.fexinidazoleMonitor Closely (1)fexinidazole will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.fluphenazineMonitor Closely (1)carisoprodol and fluphenazine both increase sedation. Use Caution/Monitor.flurazepamMonitor Closely (1)flurazepam and carisoprodol both increase sedation. Use Caution/Monitor.ganaxoloneMonitor Closely (1)carisoprodol and ganaxolone both increase sedation. Use